Diagnostic markers and prognostic factors in thyroid cancer

Menno R. Vriens, Jennifer M J Schreinemakers, Insoo Suh, Marlon A Guerrero, Orlo H. Clark

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

There has been considerable progress identifying biomarkers in thyroid tumors that improve the accuracy of fine-needle aspiration biopsy and also help predict tumor aggressiveness or behavior. In this review we address both the clinical potential of molecular biomarkers and their usefulness, based on the most recent literature. We describe the current best clinical staging systems and the common somatic mutations in thyroid cancer. The BRAF mutation is the most common mutation in papillary thyroid cancer and has recently been reported to be associated with disease aggressiveness; it is also an independent predictor of tumor behavior. Combined testing of RET/PTC, NTRK, RAS and PAX8-PPARg, which are mutually exclusive mutations, helps improve the accuracy of fine-needle aspiration biopsy. Gene-expression profiling studies have identified a variety of potential molecular markers to help distinguish benign from malignant thyroid neoplasms. Expression ana lysis of differentially expressed microRNAs also appears to be a promising diagnostic approach for distinguishing benign from malignant thyroid neoplasm. It is especially useful for indeterminate nodules by fine-needle aspiration biopsy.

Original languageEnglish (US)
Pages (from-to)1283-1293
Number of pages11
JournalFuture Oncology
Volume5
Issue number8
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Thyroid Neoplasms
Fine Needle Biopsy
Mutation
Biomarkers
Neoplasms
Factor IX
Gene Expression Profiling
MicroRNAs
Thyroid Gland

Keywords

  • Biomarkers
  • Gene-expression profiling
  • Microrna
  • Somatic mutations
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vriens, M. R., Schreinemakers, J. M. J., Suh, I., Guerrero, M. A., & Clark, O. H. (2009). Diagnostic markers and prognostic factors in thyroid cancer. Future Oncology, 5(8), 1283-1293. https://doi.org/10.2217/fon.09.85

Diagnostic markers and prognostic factors in thyroid cancer. / Vriens, Menno R.; Schreinemakers, Jennifer M J; Suh, Insoo; Guerrero, Marlon A; Clark, Orlo H.

In: Future Oncology, Vol. 5, No. 8, 2009, p. 1283-1293.

Research output: Contribution to journalArticle

Vriens, MR, Schreinemakers, JMJ, Suh, I, Guerrero, MA & Clark, OH 2009, 'Diagnostic markers and prognostic factors in thyroid cancer', Future Oncology, vol. 5, no. 8, pp. 1283-1293. https://doi.org/10.2217/fon.09.85
Vriens, Menno R. ; Schreinemakers, Jennifer M J ; Suh, Insoo ; Guerrero, Marlon A ; Clark, Orlo H. / Diagnostic markers and prognostic factors in thyroid cancer. In: Future Oncology. 2009 ; Vol. 5, No. 8. pp. 1283-1293.
@article{8f25917c620c4f2488d9ce1c13083f9c,
title = "Diagnostic markers and prognostic factors in thyroid cancer",
abstract = "There has been considerable progress identifying biomarkers in thyroid tumors that improve the accuracy of fine-needle aspiration biopsy and also help predict tumor aggressiveness or behavior. In this review we address both the clinical potential of molecular biomarkers and their usefulness, based on the most recent literature. We describe the current best clinical staging systems and the common somatic mutations in thyroid cancer. The BRAF mutation is the most common mutation in papillary thyroid cancer and has recently been reported to be associated with disease aggressiveness; it is also an independent predictor of tumor behavior. Combined testing of RET/PTC, NTRK, RAS and PAX8-PPARg, which are mutually exclusive mutations, helps improve the accuracy of fine-needle aspiration biopsy. Gene-expression profiling studies have identified a variety of potential molecular markers to help distinguish benign from malignant thyroid neoplasms. Expression ana lysis of differentially expressed microRNAs also appears to be a promising diagnostic approach for distinguishing benign from malignant thyroid neoplasm. It is especially useful for indeterminate nodules by fine-needle aspiration biopsy.",
keywords = "Biomarkers, Gene-expression profiling, Microrna, Somatic mutations, Thyroid cancer",
author = "Vriens, {Menno R.} and Schreinemakers, {Jennifer M J} and Insoo Suh and Guerrero, {Marlon A} and Clark, {Orlo H.}",
year = "2009",
doi = "10.2217/fon.09.85",
language = "English (US)",
volume = "5",
pages = "1283--1293",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Diagnostic markers and prognostic factors in thyroid cancer

AU - Vriens, Menno R.

AU - Schreinemakers, Jennifer M J

AU - Suh, Insoo

AU - Guerrero, Marlon A

AU - Clark, Orlo H.

PY - 2009

Y1 - 2009

N2 - There has been considerable progress identifying biomarkers in thyroid tumors that improve the accuracy of fine-needle aspiration biopsy and also help predict tumor aggressiveness or behavior. In this review we address both the clinical potential of molecular biomarkers and their usefulness, based on the most recent literature. We describe the current best clinical staging systems and the common somatic mutations in thyroid cancer. The BRAF mutation is the most common mutation in papillary thyroid cancer and has recently been reported to be associated with disease aggressiveness; it is also an independent predictor of tumor behavior. Combined testing of RET/PTC, NTRK, RAS and PAX8-PPARg, which are mutually exclusive mutations, helps improve the accuracy of fine-needle aspiration biopsy. Gene-expression profiling studies have identified a variety of potential molecular markers to help distinguish benign from malignant thyroid neoplasms. Expression ana lysis of differentially expressed microRNAs also appears to be a promising diagnostic approach for distinguishing benign from malignant thyroid neoplasm. It is especially useful for indeterminate nodules by fine-needle aspiration biopsy.

AB - There has been considerable progress identifying biomarkers in thyroid tumors that improve the accuracy of fine-needle aspiration biopsy and also help predict tumor aggressiveness or behavior. In this review we address both the clinical potential of molecular biomarkers and their usefulness, based on the most recent literature. We describe the current best clinical staging systems and the common somatic mutations in thyroid cancer. The BRAF mutation is the most common mutation in papillary thyroid cancer and has recently been reported to be associated with disease aggressiveness; it is also an independent predictor of tumor behavior. Combined testing of RET/PTC, NTRK, RAS and PAX8-PPARg, which are mutually exclusive mutations, helps improve the accuracy of fine-needle aspiration biopsy. Gene-expression profiling studies have identified a variety of potential molecular markers to help distinguish benign from malignant thyroid neoplasms. Expression ana lysis of differentially expressed microRNAs also appears to be a promising diagnostic approach for distinguishing benign from malignant thyroid neoplasm. It is especially useful for indeterminate nodules by fine-needle aspiration biopsy.

KW - Biomarkers

KW - Gene-expression profiling

KW - Microrna

KW - Somatic mutations

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=75649124886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649124886&partnerID=8YFLogxK

U2 - 10.2217/fon.09.85

DO - 10.2217/fon.09.85

M3 - Article

VL - 5

SP - 1283

EP - 1293

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 8

ER -